Centene Corporation
CNC
$59.55
-0.73%
Centene Corporation is a leading managed care organization specializing in government-sponsored healthcare programs, primarily Medicaid, Medicare, and individual exchange plans, serving approximately 20 million medical members. The company is a dominant player in the Medicaid managed care market, leveraging its scale and expertise in administering complex, state-sponsored health plans. The current investor narrative is heavily influenced by regulatory developments in Medicare Advantage payments, as evidenced by recent sector-wide rallies following favorable CMS updates, alongside ongoing debates regarding the company's path to restoring consistent profitability after a volatile earnings period marked by significant quarterly losses.…
CNC
Centene Corporation
$59.55
CNC 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centene Corporation's 12-month outlook, with a consensus price target around $77.41 and implied upside of +30.0% versus the current price.
Average Target
$77.41
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$48 - $77
Analyst target range
Analyst coverage is limited, with only 5 analysts providing estimates, indicating this is not a widely followed large-cap name. The consensus appears neutral, as evidenced by recent institutional ratings from firms like JP Morgan, Mizuho, and Morgan Stanley all maintaining 'Neutral' or 'Equal Weight' stances, though a notable upgrade came from Barclays moving to 'Overweight' in January 2026. The wide range between the low revenue estimate of $207.79 billion and the high of $219.04 billion signals meaningful uncertainty about the company's near-term growth trajectory, and the lack of a provided consensus price target further underscores the limited and potentially divergent analyst views, which can contribute to higher volatility and less efficient price discovery for the stock.
Bulls vs Bears: CNC Investment Factors
The investment debate for CNC is a classic battle between deep value and broken fundamentals. The bull case is anchored in an extreme valuation discount (PS of 0.104), robust revenue growth (21.86% YoY), and strong free cash flow ($4.32B), suggesting the market has over-penalized the stock. The bear case focuses on the severe and volatile profitability crisis, with consecutive multi-billion dollar quarterly losses making the earnings picture untenable. Currently, the bear side has stronger evidence due to the concrete and recent nature of the massive losses. The single most important tension is whether management can stabilize and restore consistent profitability before the cash flow buffer is eroded, thereby justifying the revenue multiple expansion the bulls anticipate. The recent powerful rally suggests the market is beginning to bet on this outcome, but the fundamental proof remains absent.
Bullish
- Extreme Undervaluation on Sales: CNC trades at a trailing Price-to-Sales ratio of 0.104, a fraction of its own historical average of 0.406 and significantly below typical healthcare plan peers. This deep discount implies the market is pricing in severe pessimism, creating a substantial margin of safety if profitability improves.
- Robust Revenue Growth Trajectory: The company delivered 21.86% year-over-year revenue growth in Q4 2025, with full-year analyst estimates pointing to over $213 billion in revenue. This demonstrates strong underlying demand for its government-sponsored healthcare plans, providing a solid top-line foundation for a turnaround.
- Strong Free Cash Flow Generation: Despite reporting significant net losses, CNC generated $4.32 billion in trailing twelve-month free cash flow. This provides a critical cushion, allowing the company to fund operations, service debt, and navigate its profitability recovery without an immediate liquidity crisis.
- Powerful Technical Recovery Trend: The stock has surged 51.5% over the past six months and 32.8% over three months, decisively breaking out from its 52-week low of $25.08. This momentum, coupled with a current price near the 52-week high ($60.76), suggests a major sentiment shift and a potential technical breakout.
Bearish
- Severe and Volatile Profitability Crisis: The company reported a net loss of $1.10 billion in Q4 2025, with a trailing net margin of -3.43%. This follows an even larger $6.63 billion loss in Q3, indicating extreme earnings volatility and a deeply broken path to consistent profitability.
- Extreme Negative Earnings Momentum: Trailing EPS is -$0.33, rendering the P/E ratio meaningless and negative. The swing from a $2.64 EPS profit in Q1 2025 to massive subsequent losses demonstrates fundamental instability that makes forecasting earnings nearly impossible.
- Limited Analyst Conviction: With only 5 analysts covering the stock and major firms like JP Morgan and Morgan Stanley maintaining 'Neutral' stances, there is a lack of strong institutional buy-in. The wide revenue estimate range ($207.8B to $219.0B) further underscores high uncertainty.
- Overextended Technical Rally: Trading at 97% of its 52-week range ($59.60 vs. $60.76 high), the stock's 51.5% six-month surge may be overextended. A failure to break above the $60.76 resistance could trigger a significant pullback, especially given the stock's beta of 1.062 implies market-correlated volatility.
CNC Technical Analysis
The stock is in a powerful recovery trend, having surged 51.5% over the past six months, decisively reversing a prior downtrend indicated by a modest 5.45% one-year gain. Currently trading at $59.60, the price sits near the top of its 52-week range ($25.08 to $60.76), representing approximately 97% of that range, signaling strong momentum but also potential overextension as it tests major resistance. Recent momentum is exceptionally strong, with the stock up 32.8% over three months and 10.41% over one month, significantly outperforming the SPY's 10.28% and 6.31% gains over the same periods, respectively; this acceleration suggests the recovery is gaining steam, though the 1-month relative strength of +4.10% indicates it is beginning to cool slightly from its peak pace. Key technical support is anchored at the 52-week low of $25.08, while immediate resistance is at the 52-week high of $60.76; a confirmed breakout above $60.76 would signal a new bullish phase, whereas a failure could lead to consolidation. With a beta of 1.062, the stock exhibits volatility roughly in line with the broader market, which, combined with a short ratio of 2.11, suggests a moderate level of speculative interest and near-term price sensitivity.
Beta
1.06
1.06x market volatility
Max Drawdown
-59.9%
Largest decline past year
52-Week Range
$25-$62
Price range past year
Annual Return
+7.5%
Cumulative gain past year
| Period | CNC Return | S&P 500 |
|---|---|---|
| 1m | +11.2% | +5.0% |
| 3m | +37.6% | +10.7% |
| 6m | +55.3% | +10.0% |
| 1y | +7.5% | +26.5% |
| ytd | +42.5% | +10.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNC Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue reaching $49.73 billion, representing a 21.86% year-over-year increase; however, this growth is overshadowed by severe profitability issues, as the same quarter saw a net loss of $1.10 billion and an operating loss of $1.74 billion. The company is currently unprofitable on a trailing basis, with a net margin of -3.43% and an operating margin of -3.91% for the latest period; gross margin improved to 15.18% in Q4 from 6.05% in Q2 2025, indicating some operational recovery, but the path from deep losses in Q3 (-$6.63B net income) to the smaller Q4 loss suggests a volatile and challenging journey toward stability. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.94, and liquidity is adequate with a current ratio of 1.68; critically, the company generated $4.32 billion in trailing twelve-month free cash flow, providing substantial internal funding for operations and debt service, which mitigates some financial risk despite the reported losses.
Quarterly Revenue
$49.7B
2025-12
Revenue YoY Growth
+0.21%
YoY Comparison
Gross Margin
+0.15%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNC Overvalued?
Given the negative trailing net income of -$1.10 billion, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is a very low 0.104, while the forward-looking metric is not directly provided, but the market cap of $20.21 billion against estimated revenue of $213.12 billion implies a forward PS of approximately 0.095, suggesting the market expects revenue growth to continue but with minimal multiple expansion. Compared to typical healthcare plan peers, a PS ratio below 0.2 represents a significant discount, which may be justified by the company's current lack of profitability and earnings volatility, but also presents a potential value opportunity if the profitability trajectory improves. Historically, the stock's own PS ratio has fluctuated, recently at 0.406 as of Q4 2025 per the historical ratios data; the current PS of 0.104 is near the extreme low end of its historical range, indicating the market is pricing in substantial pessimism, which could either signify a deep-value setup or reflect justified concerns about fundamental deterioration.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -72x~220x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: CNC's primary risk is its severe and volatile profitability. The company swung from a $1.31 billion net profit in Q1 2025 to a $6.63 billion loss in Q3, followed by a $1.10 billion loss in Q4. This erratic performance, with a trailing net margin of -3.43%, creates immense uncertainty around future earnings and calls into question the sustainability of its business model. While strong free cash flow of $4.32 billion provides a near-term buffer, a debt-to-equity ratio of 0.94 adds fixed-cost pressure. The risk is that revenue growth alone cannot fix the underlying cost and pricing issues leading to these losses.
Market & Competitive Risks: The stock's 51.5% six-month rally has pushed it to the top of its 52-week range, creating valuation compression risk if the profitability recovery narrative falters. With a beta of 1.062, CNC's price action is correlated with the broader market, making it susceptible to a sector-wide derating of unprofitable growth stocks. Competitive risks are inherent in the government-sponsored healthcare market, where pricing is heavily regulated and contract renewals are competitive. The recent positive CMS news on Medicare Advantage payments is a tailwind, but future regulatory changes could reverse this benefit.
Worst-Case Scenario: The worst-case scenario involves CNC failing to stem its losses, leading to consecutive quarters of negative earnings that erode its cash balance and force a dilutive capital raise or debt restructuring. A broader market downturn coinciding with an earnings miss could trigger a rapid de-rating. In this adverse scenario, the stock could realistically revisit its 52-week low of $25.08, representing a downside of approximately -58% from the current price of $59.60. The historical maximum drawdown of -59.93% supports the potential for such a severe decline if sentiment reverses.